Which regimen is used to treat CD20-positive acute lymphoblastic leukemia (ALL)?

Updated: Jul 02, 2021
  • Author: Karen Seiter, MD; Chief Editor: Matthew C Foster, MD  more...
  • Print


See the list below:

  • CD20 positivity is an adverse prognostic factor in ALL

  • In 143 adults with Ph– B-cell precursor (BCP) ALL treated in the Group for Research on Adult Acute Lymphoblastic Leukemia (GRAALL) 2003 trial, CD20 positivity was associated with a higher cumulative incidence of relapse at 42 mo, independent of the ALL high-risk subset [14]

  • Rituximab is a monoclonal antibody that targets CD20; a trial with hyper-CVAD and rituximab 375 mg/m2 on days 1 and 11 of cycles 1, 3, 5, and 7 and on days 1 and 8 of cycles 2, 4, 6 and 8 resulted in a complete remission rate of 86%; 3-y overall survival (OS), event-free survival, and disease-free survival rates were 89%, 80%, and 88%, respectively [15]

Did this answer your question?
Additional feedback? (Optional)
Thank you for your feedback!